Immutep Reports Improving Results from INSIGHT-004 Trial
41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%) Encouraging early anti-tumour activity signals in a variety of cancer indications not typically sensitive to immune checkpoint …